Table 1 Efficacy trials of acellular pertussis vaccine [10, 64, 65]
From: The Pertussis resurgence: putting together the pieces of the puzzle
Study year | Study location/name | Design and methods | Number of participants | Comments. |
|---|---|---|---|---|
1985 [18] | Sweden, Stockholm | Double blind placebo controlled (compared two Japanese aP vaccines) | 3801 | No wP control group. 2 dose schedule |
1991 [66] | Sweden GÖteborg | Double blind placebo controlled (compared DT/DTP) | 3450 | No wP control 3 dose schedule. |
1992 [67] | Germany, Mainz | Passive monitoring of household contacts | 360 contacts | 3 dose schedule |
1992 [68] | Sweden, Stockholm | Double blind placebo controlled (two-compenent aP/five component aP/wP/DT) | 24,336 | wP control – (Conaught) 3 dose schedule |
1992 [69] | Italy | Double blind placebo controlled (aP/wP/DT) | 14,751 | wP control – (Conaught) 3 dose schedule |
1993 [70] | Germany, Munich | Case control study (aP/wP/DT/no vaccine) | 16780 | 3 dose schedule |
1990 [71] | Senegal | -Double blind placebo controlled -Household contact (aP/wP) | 4181 | No placebo control 3 dose schedule |
Late 90′s [72] | Germany, Erlangen | Prospective study, 2 groups randomized to aP or wP, third group (not randomized) received DT. |  | 4 dose schedule |